实践指南更新建议摘要:意识障碍
该指南由美国神经病学学会(AAN)、美国康复医学大会(ACRM)和国家残疾、独立生活与康复研究研究所联合更新,基于系统评价证据和改良德尔菲共识,针对成人及儿童迁延性意识障碍(DoC)提出诊断、预后、治疗和护理建议,强调识别混杂因素、优化觉醒、系列标准化评估,以及金刚烷胺用于特定成人患者。
要点
- 识别并治疗混杂因素、优化觉醒、系列标准化评估以提高诊断准确性(B级)。
- 成人MCS(vs VS/UWS)及创伤性病因预后更佳,应告知家属(B级)。
- 金刚烷胺(100-200 mg bid)用于伤后4-16周创伤性VS/UWS或MCS成人以促进恢复(B级)。
核心结论
- 临床医生应识别并治疗混杂因素、优化觉醒、进行系列标准化评估以提高成人和儿童迁延性DoC的诊断准确性(B级)。
- 成人MCS(vs VS/UWS)和创伤性(vs 非创伤性)病因与更有利结局相关,应告知家属(B级)。
- 预后差时须讨论长期护理(A级),但应承认预后并非普遍差(B级)。
- 金刚烷胺(100-200 mg bid)可用于伤后4-16周创伤性VS/UWS或MCS成人以加速功能恢复和减少残疾(B级)。
- 疼痛应始终评估和治疗(B级),并讨论支持治疗方法的证据(B级)。
研究设计与样本
- 基于系统评价证据、相关证据、护理原则和推论,采用改良德尔菲共识过程,遵循AAN 2011过程手册(经修订)。
主要发现
- 成人MCS(vs VS/UWS)和创伤性(vs 非创伤性)病因与更有利结局相关(B级)。
- 结构MRI、SPECT和Coma Recovery Scale-Revised可辅助成人预后判断(B级);无检测显示可提高儿童预后准确性。
- 近期证据表明「chronic VS/UWS」应取代「permanent VS」,并注明持续时间(B级)。
关键数值与推荐
- 金刚烷胺剂量100-200 mg bid,用于伤后4-16周创伤性VS/UWS或MCS成人(B级)。
- 识别并治疗混杂因素、优化觉醒、系列标准化评估(B级)。
- 疼痛始终评估和治疗(B级)。
- 预后差时讨论长期护理(A级),承认预后并非普遍差(B级)。
临床怎么用
- 对成人和儿童迁延性DoC识别并治疗混杂因素、优化觉醒、系列标准化评估。
- 告知家属成人MCS(vs VS/UWS)和创伤性病因预后更佳。
- 对伤后4-16周创伤性VS/UWS或MCS成人处方金刚烷胺(100-200 mg bid)。
- 始终评估和治疗疼痛,并讨论支持治疗方法的证据。
- 使用「chronic VS/UWS」替代「permanent VS」并注明持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To update the 1995 American Academy of Neurology (AAN) practice parameter on persistent vegetative state and the 2002 case definition on minimally conscious state (MCS) and provide care recommendations for patients with prolonged disorders of consciousness (DoC). METHODS: Recommendations were based on systematic review evidence, related evidence, care principles, and inferences using a modified Delphi consensus process according to the AAN 2011 process manual, as amended. RECOMMENDATIONS: Clinicians should identify and treat confounding conditions, optimize arousal, and perform serial standardized assessments to improve diagnostic accuracy in adults and children with prolonged DoC (Level B). Clinicians should counsel families that for adults, MCS (vs vegetative state [VS]/ unresponsive wakefulness syndrome [UWS]) and traumatic (vs nontraumatic) etiology are associated with more favorable outcomes (Level B). When prognosis is poor, long-term care must be discussed (Level A), acknowledging that prognosis is not universally poor (Level B). Structural MRI, SPECT, and the Coma Recovery Scale-Revised can assist prognostication in adults (Level B); no tests are shown to improve prognostic accuracy in children. Pain always should be assessed and treated (Level B) and evidence supporting treatment approaches discussed (Level B). Clinicians should prescribe amantadine (100-200 mg bid) for adults with traumatic VS/UWS or MCS (4-16 weeks post injury) to hasten functional recovery and reduce disability early in recovery (Level B). Family counseling concerning children should acknowledge that natural history of recovery, prognosis, and treatment are not established (Level B). Recent evidence indicates that the term chronic VS/UWS should replace permanent VS, with duration specified (Level B). Additional recommendations are included.
引用
- Giacino JT, Katz DI, Schiff ND, et al. Practice Guideline Update Recommendations Summary: Disorders of Consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Arch Phys Med Rehabil. 2018. PMID: 30098791. doi:10.1016/j.apmr.2018.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。